Regulatory Agios mulls early FDA filing for sickle cell therapy PharmaphorumAgios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.RegulatoryHematologyRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaphorum Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months. RegulatoryHematologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biogen uplifts rare disease pipeline with $5.6bn Apellis buyoutNext: A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
